Volume 12, Number 9—September 2006
Early Neuroschistosomiasis Complicating Katayama Syndrome
To the Editor: Neurologic complications of schistosomiasis may occur early as well as late in the course of infection; they result when a pair of worms becomes lodged in the vasculature, and their eggs become trapped in the microcirculation of the brain or spinal cord. There, they elicit a strong inflammatory response, which causes the clinical manifestations (1–3). Magnetic resonance and computed tomographic images of the brain show nonspecific, contrast-enhancing infiltrates, which suggests brain tumors (4). Definitive diagnosis requires finding Schistosoma eggs in feces, urine, rectal biopsy specimen, or biopsy specimen of central nervous system lesions (5), while a positive antibody test result provides a probable diagnosis only. To prevent irreversible damage, early treatment with corticosteroids is essential, after which the adult worms can be eliminated with praziquantel (3,4). A high degree of suspicion is therefore needed to avoid treatment delay.
Neuroschistosomiasis has been reported in persons living near Lake Malawi, in Malawi (6). Four members of a Belgian expatriate family (both parents and 2 children, a 12-year-old boy and a 7-year-old girl) went swimming in Lake Malawi in September 1998. On the advice of a physician, they took praziquantel 2 weeks afterward as postexposure prophylaxis. Nevertheless, fever, hypereosinophilia, cough, and abdominal discomfort developed in the mother and both children 6–8 weeks after they had been swimming; these symptoms were indicative of Katayama syndrome. The father remained asymptomatic but had a moderately raised eosinophil count (760 cells/mm3) and tested positive for Schistosoma antibodies. Schistosoma hematobium eggs were found in feces and urine of the mother and girl. All family members tested negative for schistosomiasis on a screening visit the previous year. The boy was admitted to a Zambian hospital because of high fever, cough, and a pulmonary infiltrate. He did not improve on antimicrobial drugs given for suspected pneumonia, and a gradually worsening neurologic syndrome developed, with left-sided hemiparesis, slurred speech, and slow movements.
The boy's condition prompted repatriation ≈10 weeks after the exposure. On admission at the University Hospital of Antwerp, his symptoms included fever, left-sided paresis with left-sided Babinski sign, and high eosinophil count (3,080 cells/mm3). An ELISA for Schistosoma antibodies was weakly positive. Examination of spinal fluid showed normal cell and protein content and a slightly lowered glycorrachia. A nuclear magnetic resonance (NMR) image of the brain showed multiple, small, contrast-enhanced white matter lesions around the semiovale center (cranially from the lateral ventricles) bilaterally and in the right parietal cortex. A tentative diagnosis of acute neuroschistosomiasis was made, and the patient was given corticosteroids with praziquantel, 750 mg twice a day for 14 days. At the end of this treatment, his condition had markedly improved; discrete hemiparesis was the only residual symptom. One month later, the patient had returned to normal, apart from left leg hyperreflexia. An NMR of the brain still showed residual lesions around the semiovale centers. Ten months later, results of clinical and neurologic examinations were normal, but NMR of the brain still showed minor residual lesions around the semiovale center on the right side. During follow-up, a serologic shift (indirect hemagglutination schistosomal antibody test) was seen, and eosinophil count decreased gradually to normal (Table). Although the boy never excreted eggs, S. hematobium infection was presumptively diagnosed on the basis of active infection in his relatives and the response to treatment.
When neurologic symptoms appear soon after primary infection with Schistosoma flukes, confirming the diagnosis may prove difficult, and schistosomiasis should be suspected when the patient has bathed in potentially infected water. Furthermore, hypereosinophilia is an early warning sign, as seroconversion and egg excretion may be slower to evolve. Both elements provide sufficient circumstantial evidence to strongly suspect the diagnosis (2). In this case, the full-blown Katayama syndrome contributed to the evidence.
Praziquantel only kills adult worms and does not inactivate schistosomules, nor the miracidium inside the eggs, which will continue to elicit a damaging immunologic response for some time. Early antischistosomal treatment might, in fact, worsen symptoms (7). Because schistosomules may require up to 8 weeks to mature, early postexposure treatment with praziquantel cannot be used to forestall disease after primary infection. Furthermore, Katayama syndrome may occur as early as 3 weeks after exposure. On the other hand, withholding praziquantel until larvae have matured (8 weeks after exposure) would not prevent Katayama syndrome in many cases (7). Acute symptoms, including early neuroschistosomiasis, may therefore still develop during this 5-week window after exposure, despite early praziquantel administration.
Artemether has shown promising activity against schistosomules (8). Repeated administration throughout the transmission season has prevented Katayama syndrome in S. japonicum infection (9). Its use, singly or in combination with praziquantel, should be investigated as true postexposure prophylaxis for primary schistosomal infection in nonimmune travelers (10).
- Pittella JE, Lana-Peixato MA. Brain involvement in hepatosplenic schistosomiasis mansoni. Brain. 1981;104:621–32.
- Granier H, Potard M, Diraison P, Nicolas X, Laborde JP, Tlarmin F. Acute encephalitis concurrent with primary infection by Schistosoma mansoni. Med Trop (Mars). 2003;63:60–3.
- Ferrari TC, Moreira PR, Cunha AS. Spinal cord schistosomiasis: a prospective study of 63 cases emphasizing clinical and therapeutic aspects. J Clin Neurosci. 2004;11:246–53.
- Silva LCS, Maciel PE, Ribas JGR, Souza-Pereira SR, Natunes CM, Lambertucci JR. Treatment of schistosomal myeloradiculopathy with praziquantel and corticosteroids and evaluation by magnetic resonance imaging: a longitudinal study. Clin Infect Dis. 2004;39:1618–24.
- Nascimento-Carvalho CM, Moreno-Carvalho OA. Clinical and cerebrospinal fluid findings in patients less than 20 years old with a presumptive diagnosis of neuroschistosomiasis. J Trop Pediatr. 2004;50:98–100.
- Naus CW, Chipwete J, Visser LG, Zijlstra EE, van Lieshout L. The contribution made by Schistosoma infection to non-traumatic disorders of the spinal cord in Malawi. Ann Trop Med Parasitol. 2003;97:711–21.
- Grandière-Perez L, Ansart S, Paris L, Faussart A, Jaureguiberry S, Grivois B, Efficacy of praziquantel during the incubation and invasive phase of Schistosoma hematobium schistosomiasis in 18 travelers. Am J Trop Med Hyg. 2006;74:814–8.
- Xiao S, Tanner M, N'Goran EK, Utzinger J, Chollet J, Bergquist R, Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop. 2002;82:175–81.
- Li YS, Chen HG, He HB, Hou XY, Ellis M, McManus DP. A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China. Acta Trop. 2005;96:184–90.
- Utzinger J, Keiser J, Shuhua X, Tanner M, Singer BH. Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob Agents Chemother. 2003;47:1487–95.
Suggested citation for this article: Clerinx J, van Gompel A, Lynen L, Ceulemans B. Neuroschistosomiasis with early Katayama syndrome [letter]. Emerg Infect Dis [serial on the Internet]. 2006 Sep [date cited]. http://dx.doi.org/10.3201/eid1209.060113
Please use the form below to submit correspondence to the authors or contact them at the following address:
Jan Clerinx, Institute of Tropical Medicine, Nationalestraat 155, B-2000 Antwerp, Belgium
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: November 17, 2011
- Page last updated: November 17, 2011
- Page last reviewed: November 17, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)